We demonstrated that equipotent pan‐PI3K/mTOR inhibition by gedatolisib was more effective than the other PAM inhibitors at attenuating multiple PAM‐controlled cellular and metabolic functions driving tumor growth, including protein synthesis, cell cycle progression, cell survival, and cell migration. This evidence concerns the gene PIK3CA and neoplasm.